Sarepta Therapeutics names Michael Severino CEO as rare-disease sector tests its next pipeline cycle

The rare-disease genetic medicine sector is pressing into a new commercial and pipeline cycle, with approved gene therapies requiring broader distribution reach and next-generation siRNA programs advancing toward proof-of-concept data. Against that backdrop, Sarepta Therapeutics (NASDAQ: SRPT) confirmed on July 27, 2026 that Michael Severino, M.D. will become chief executive officer effective July 28, succeeding Doug Ingram, who is retiring after leading the company through its most consequential regulatory period.

A succession built around pipeline execution

Severino brings more than 25 years of biopharmaceutical experience. The clearest read-through from his record is a pattern of R&D scale-up: at AbbVie, where he served as Vice Chairman and President overseeing research and development and the corporate strategy office, he built the pipelines behind Rinvoq, Skyrizi, and Venclexta, and extended the company into hematologic oncology, immunology, and neuroscience. Before AbbVie, he was Senior Vice President, Global Development and Chief Medical Officer at Amgen, overseeing clinical development across oncology, inflammation, neuroscience, cardiovascular, and metabolic disorders. He also spent time at Merck as a Senior Director leading research in clinical genomics, molecular profiling, and experimental medicine. Most recently, Severino was CEO of Tessera Therapeutics and a CEO-Partner at Flagship Pioneering, roles he held since 2022.

Where Sarepta sits in the sector cycle

Sarepta holds a leadership position in Duchenne muscular dystrophy. Ingram's tenure produced two exon-skipping treatment approvals and the first one-time gene therapy approved for the disease. The siRNA pipeline programs are next. Severino cited long-term data from approved products and preclinical and clinical siRNA data as factors in his decision to join. The broader cycle for precision genetic medicine now rewards executives who can run an established commercial franchise while simultaneously advancing a next-generation modality. Cross-border demand for rare-disease therapies has followed orphan-drug incentive structures in major markets, keeping pricing and access dynamics active for any incoming CEO.

Board transition and the incoming term

Severino will also join Sarepta's Board of Directors. M. Kathleen Behrens, Ph.D., Chairperson of the Board, said the search identified multiple candidates before settling on Severino, citing his scientific depth, development expertise, and execution record across franchises. Ingram will remain in an advisory capacity through the end of 2026. Severino currently serves on the boards of Avantor, Montai Health, Quotient Therapeutics, and Viatris. He holds a B.S. in Biochemistry from the University of Maryland, an M.D. from Johns Hopkins University, and completed his training at Massachusetts General Hospital and Harvard Medical School. The transition lands as siRNA clinical data readouts and the company's ability to maintain FDA approval compliance on existing products become the metrics his tenure will be measured against.

Related reading

• Global morbidity gap widens across 203 countries as survival gains outpace healthy aging, Lancet study finds
• Four forces drove a bruising week for equities